Melanotan I
Also known as Afamelanotide, Scenesse, MT-1, CUV1647
A 13-amino acid synthetic analog of α-MSH that stimulates melanin production. FDA approved for erythropoietic protoporphyria. Unlike MT-II, minimal affinity for MC3R and MC4R.
Regulatory Pathway
Dosing Protocol
Typical Dose
500-1000 mcg daily (loading), 500-1000 mcg 1-2x weekly (maintenance)
Frequency
Daily during loading (1-2 weeks), then 1-2x weekly maintenance
Duration
Long-term / as needed before sun season
Timing & Administration
Administer via Subcutaneous implant (FDA version); subcutaneous injection (off-label). Frequency: Daily during loading (1-2 weeks), then 1-2x weekly maintenance.
Popular Uses
Mechanism of Action
Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin synthesis. Unlike MT-II, has minimal affinity for MC3R and MC4R, resulting in fewer sexual and appetite-related side effects.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved (2019) - Erythropoietic Protoporphyria.
Side Effects & Safety
Important Warnings
- FDA-approved version uses implant form
- Off-label injection use is not approved.
References
No references available.
Related Peptides
Browse all →A naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Widely used in skincare for its wound healing and anti-aging properties.
View profileA cosmetic peptide that reduces wrinkles by inhibiting muscle contraction. Studies show up to 63% reduction in wrinkle depth over 28 days.
View profileA popular cosmetic peptide that reduces facial wrinkles by inhibiting neurotransmitter release. Studies show 30% reduction in wrinkle depth after 30 days.
View profile